A recent meta-analysis of the anti-TNF antibody agents infiximab and adalumimab in 3493 patients with rheumatoid arthritis demonstrated increased risk of serious infections in 126 patients but only 1 case of coccidioidomycosis [9]. This evidence concerns the gene TNF and coccidioidomycosis.